ArQule receives milestone payment from Wyeth

By Lisa Kerner

Erie, Pa., April 18 - ArQule, Inc. said it received a milestone payment from Wyeth in connection with Wyeth's filing of an Investigational New Drug application with the Food and Drug Administration for a compound under development for Alzheimer's disease.

The payment amount was not disclosed.

As with its other established chemistry collaboration agreements, ArQule receives fees for services, as well as milestone and royalty payments based on development milestones for compounds it provides, according to a news release.

ArQule is a Woburn, Mass.-based biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.